Cost-effectiveness of first-line osimertinib plus chemotherapy versus amivantamab plus lazertinib for advanced EGFR-mutant NSCLC in the US and China

Yihong Guo, Shixian Liu, Chuang Yang, Chengjun Wang, Rongyu Zhang, Yunfei Wang, Yanan Song, Mingfei Liu, Ruolin Zhang, Tiantian Xuan, Wen Zhao, Jisheng Li

Therapeutic Advances in Medical Oncology

Published online on July 25, 2026

Abstract

Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:The FLAURA2 and MARIPOSA trials established survival benefits of osimertinib plus chemotherapy and amivantamab plus lazertinib, respectively, over osimertinib monotherapy in advanced non-small cell lung cancer (NSCLC) patients with epidermal ...